Literature DB >> 18493104

Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in the Japanese population.

Masako Zenibayashi1, Kazuaki Miyake, Yukio Horikawa, Yushi Hirota, Tetsuya Teranishi, Kunichi Kouyama, Kazuhiko Sakaguchi, Jun Takeda, Masato Kasuga.   

Abstract

AIMS: A missense mutation in the low density lipoprotein receptor-related protein 6 gene (LRP6) was recently shown to be responsible for a disorder characterized by early-onset coronary artery disease as well as diabetes mellitus (DM), hyperlipidemia, hypertension, and osteoporosis. Mice deficient in LRP5, a closely related paralog of LRP6, manifest a marked impairment in glucose tolerance. The aim of the present study was to examine whether common variants of LRP5 and LRP6 are associated with Type 2 DM or dyslipidemia in Japanese individuals.
METHODS: Thirteen single nucleotide polymorphisms (SNPs) of LRP6 and nine SNPs of LRP5 were genotyped in a total of 608 Type 2 DM patients and 366 nondiabetic control subjects (initial study). An association analysis was then performed for each SNP and for haplotypes. For some of the SNPs, we provided another sample panel of 576 cases and 576 controls for the replication study. The relation to clinical characteristics was also examined in diabetic subjects.
RESULTS: In the initial study, three SNPs of LRP6 were found to be associated with susceptibility to Type 2 DM. However, this association was not detected in the replication panel. None of SNPs in LRP5 were associated with Type 2 DM in the initial panel. Neither LRP6 nor LRP5 was associated with body mass index, HOMA-beta, HOMA-IR or serum lipid concentrations.
CONCLUSIONS: We found no evidence for a substantial effect of LRP5 or LRP6 SNPs on susceptibility to type 2 diabetes or clinical characteristics of diabetic subjects in Japanese population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493104     DOI: 10.1507/endocrj.k08e-021

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

Review 1.  Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases.

Authors:  Z-M Wang; J-Q Luo; L-Y Xu; H-H Zhou; W Zhang
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

2.  Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.

Authors:  D Foer; M Zhu; R L Cardone; C Simpson; R Sullivan; S Nemiroff; G Lee; R G Kibbey; K F Petersen; K L Insogna
Journal:  Osteoporos Int       Date:  2017-03-10       Impact factor: 4.507

3.  Association of LRP5 gene polymorphism with type 2 diabetes mellitus and osteoporosis in postmenopausal women.

Authors:  Miao Xuan; Yonglan Wang; Wenxing Wang; Jun Yang; Ying Li; Xiuzhen Zhang
Journal:  Int J Clin Exp Med       Date:  2014-01-15

4.  Association of Canonical Wnt/β-Catenin Pathway and Type 2 Diabetes: Genetic Epidemiological Study in Han Chinese.

Authors:  Jinjin Wang; Jingzhi Zhao; Jianfeng Zhang; Xinping Luo; Kaiping Gao; Ming Zhang; Linlin Li; Chongjian Wang; Dongsheng Hu
Journal:  Nutrients       Date:  2015-06-15       Impact factor: 5.717

Review 5.  Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.

Authors:  Gwang-woong Go
Journal:  Nutrients       Date:  2015-06-03       Impact factor: 5.717

6.  Integrative Analyses of Genes Associated with Subcutaneous Insulin Resistance.

Authors:  Manoj Kumar Pujar; Basavaraj Vastrad; Chanabasayya Vastrad
Journal:  Biomolecules       Date:  2019-01-22

7.  Genetic variants in the WNT signaling pathway are protectively associated with colorectal cancer in a Saudi population.

Authors:  Narasimha Reddy Parine; Nahla A Azzam; Jilani Shaik; Abdulrahman M Aljebreen; Othman Alharbi; Majid A Almadi; Mohammad Alanazi; Zahid Khan
Journal:  Saudi J Biol Sci       Date:  2018-05-17       Impact factor: 4.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.